Endocrine Today Current Issue
The following articles appeared in the print edition of Endocrine Today.
Table of Contents
- Cardiovascular problems in Turner syndrome are a major concern
-
- HAPO results leading to gestational diabetes recommendations
- FDA: Atrial fibrillation events rare in patients taking oral bisphosphonates
- A man who simply won’t lose weight Ronald Tamler, MD, PhD, MBA
- Diabetes and polycystic ovary disease Ronald Tamler, MD, PhD, MBA
- In goal setting, let your patient lead Amparo Gonzalez, RN, BSN, CDE
- Easing transitions with gender assignment Anne Tamar-Mattis, JD
- Preempting patient safety L.J. Deftos, MD, JD, LLM
- Arsenic: medicinal double-edged sword
-
- Granular cell tumor of the pituitary: a rare sellar tumor Geunwon Kim, MD, PhD; Stephanie L. Lee, MD, PhD, ECNU
- Medicare Part D Richard O. Dolinar, MD
- Consider ethnic, cultural influences on childhood obesity
- Depression, appearance concerns predicted disturbed eating behavior in girls with diabetes
- Gut-derived serotonin regulated bone formation
- HT skin cream, patch formulations associated with lower risk for MI
- Inhaled insulin improved glycemic control better than powder
- Investigational GH drug increased muscle mass in older adults
-
- Low-dose aspirin did not prevent cardiovascular events in patients with type 2 diabetes
- Metformin linked with decreased CV risk, rosiglitazone linked with increased risk
- New hormone data can predict menopause within one year
- Patients with high-normal thyroid function at increased risk for atrial fibrillation
- Preteens, teens doubled use of diabetes drugs
- Risk for maternal, newborn complications lower for women who underwent bariatric surgery
- WHI: Several thrombotic, inflammatory, lipid, genetic biomarkers linked with CHD
- Women with PCOS benefited from statin therapy
-
- Bisphenol A may affect human reproduction
- Increasing obesity rate related to increased cost to society Brant K. Oelschlager, MD; Saad Shebrain, MD
- One nurse, two dietitians help give diabetes care in the Marshall Islands
- What’s in the pipeline for new type 2 diabetes drugs? June Felice Johnson, BS, PharmD, FASHP, CDM-diabetes